<DOC>
	<DOCNO>NCT02685345</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety DS-8500a compare placebo patient type 2 diabetes mellitus ( T2DM ) receive sitagliptin .</brief_summary>
	<brief_title>A Study DS-8500a Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin</brief_title>
	<detailed_description>In patient type 2 diabetes mellitus treat sitagliptin , efficacy safety DS-8500a evaluate 28-day multiple oral administration DS-8500a 25 75 mg , double-blind , placebo-controlled , parallel-group comparison study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Japanese patient type 2 diabetes Patients age ≥ 20 year time informed consent Patients treat sitagliptin 50 mg monotherapy treatment type 2 diabetes mellitus Patients HbA1c ≥ 7.0 % &lt; 9.0 % Patients type 1 diabetes mellitus history diabetic coma , precoma , ketoacidosis Patients receive require treatment insulin Patients body mass index ( BMI ) &lt; 18.5 kg/m2 ≥ 35.0 kg/m2 Patients clinically evident renal impairment ( estimate glomerular filtration rate [ eGFR ] &lt; 45 mL/min per 1.73 m2 ) clinically significant renal disease Patients fast plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>adult</keyword>
	<keyword>Phase 2</keyword>
</DOC>